Viewing nowCombinationGlossitapomin Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202300846 · Approved 2023.03.13 · Insurance code 693202570
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling blood sugar levels. The sitagliptin and metformin components work together when combined with diet and exercise therapy to effectively manage blood sugar levels. This allows for more stable blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is a diabetes treatment that contains both sitagliptin and metformin. First, allergic reactions may occur during the course of taking this medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, you should immediately stop taking the medication and inform your physician. Additionally, this medication may cause pancreatitis, a condition involving inflammation of the pancreas, so if sudden abdominal pain, nausea, vomiting, or fever occur, you should visit the hospital immediately. Due to the metformin component, rare complications such as severe lactic acidosis may occur, so if you experience symptoms such as shortness of breath, muscle pain, fatigue, abdominal pain, or altered consciousness, you should immediately stop taking this medication and consult with a healthcare professional. This medication should not be used in patients with severely impaired kidney function or with acute conditions that can affect kidney function such as severe infections, heart failure, acute myocardial infarction, or sepsis. In cases where iodine contrast agents are administered for radiological examinations, this medication should be discontinued for a certain period before and after the examination, and it should be resumed only after confirming normal kidney function. It is advisable for pregnant women or those who may become pregnant, as well as breastfeeding women, to avoid taking this medication. During treatment with this medication, it is important to be cautious since symptoms of hypoglycemia may occur when used with other medications that have strong blood sugar-lowering effects or with insulin. Moreover, patients with irregular eating habits, insufficient food intake, or those engaging in vigorous exercise, and those allergic to certain pigment components should also be careful when using this medication. During treatment, side effects such as diarrhea, nausea, vomiting, headache, or upper respiratory tract infections may occur, so it is advisable to consult a physician if symptoms are severe or persistent. This medication should be taken while regularly monitoring kidney and liver function, and special caution should be taken particularly for the elderly or patients with impaired kidney function. Finally, alcohol consumption may increase the risk of side effects associated with this medication, so it is important to avoid excessive drinking during treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is important to maintain the storage temperature between 1 degree and 30 degrees Celsius to preserve the effectiveness of the medication.
Pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.